The Efficacy and Drug Resistance Molecular Biology of Apatinib Combined With EGFR-TK1 Treated for Advanced Slow-progressed Non-Small Cell Lung Cancer (NSCLC)

Sponsor
Beijing Chest Hospital
Study ID
NCT03811054
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Apatinib（250mg/d） combined with EGFR-TKI — DRUG
    Patients with advanced non-small cell lung cancer (NSCLC) who had treated with EGFR-TKI and progressed slowly because of resistance are underwent with apatinib mesylate and continuous EGFR-TKI.

Study Details

Patients with advanced non-small cell lung cancer (NSCLC) who progress slowly after Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors（EGFR-TKI）resistance. The purpose of this study is to investigate the efficacy and drug resistance mechanism of Apatinib combine with EGFR-TK1 treated for advanced slow progressed non-small cell lung cancer and provide new treatment options.

Key Dates

Start date
Dec 1, 2018
Status verified
Jan 2019
Primary completion
Dec 31, 2020
Completion
Dec 31, 2020

Study Design

Enrollment
60 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Apatinib combined with EGFR-TKI
    Apatinib 250 millgram（mg/day（d））combined with EGFR-TKI

Primary Outcome Measure

Objective response rates (ORR) [ Time Frame: two years ]

Central Contacts

Related Studies